Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | JAK2 Y931C |
Gene Variant Detail | |
Relevant Treatment Approaches | JAK Inhibitor (Pan) JAK2 Inhibitor |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
JAK2 V617F JAK2 Y931C | cancer | resistant | Ruxolitinib | Preclinical | Actionable | In a preclinical study, cells harboring the JAK2 V617F/Y931C double mutation displayed resistance to ATP-competetive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331). | 21393331 |
JAK2 V617F JAK2 Y931C | Advanced Solid Tumor | sensitive | Fedratinib | Preclinical - Cell culture | Actionable | In a preclinical study, Inrebic (fedratinib) treatment inhibited colony formation and proliferation of transformed cells expressing JAK2 V617F and Y931C in culture (PMID: 26419724). | 26419724 |
JAK2 V617F JAK2 Y931C JAK2 S1025C | Advanced Solid Tumor | resistant | Fedratinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing JAK2 V617F, Y931C and S1025C demonstrated resistance to Inrebic (fedratinib) treatment in culture (PMID: 26419724). | 26419724 |
JAK2 V617F JAK2 Y931C JAK2 Y1045W | Advanced Solid Tumor | resistant | Fedratinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing JAK2 V617F, Y931C and Y1045W demonstrated resistance to Inrebic (fedratinib) treatment in culture (PMID: 26419724). | 26419724 |
JAK2 V617F JAK2 Y931C JAK2 F1061W | Advanced Solid Tumor | resistant | Fedratinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing JAK2 V617F, Y931C and F1061W demonstrated resistance to Inrebic (fedratinib) treatment in culture (PMID: 26419724). | 26419724 |
JAK2 V617F JAK2 Y931C JAK2 V1075F | Advanced Solid Tumor | resistant | Fedratinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing JAK2 V617F, Y931C and V1075F demonstrated resistance to Inrebic (fedratinib) treatment in culture (PMID: 26419724). | 26419724 |
JAK2 V617F JAK2 Y931C | hematologic cancer | resistant | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing the JAK2 V617F and JAK2 Y931C double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 21926964). | 21926964 |
JAK2 V617F JAK2 Y931C | hematologic cancer | resistant | Momelotinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing the JAK2 V617F and JAK2 Y931C double mutation demonstrated resistance to Momelotinib in culture (PMID: 21926964). | 21926964 |
JAK2 V617F JAK2 Y931C | hematologic cancer | resistant | AZD1480 | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing the JAK2 V617F and JAK2 Y931C double mutation demonstrated resistance to AZD1480 in culture (PMID: 21926964). | 21926964 |
JAK2 V617F JAK2 Y931C | hematologic cancer | resistant | Lestaurtinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing the JAK2 V617F and JAK2 Y931C double mutation demonstrated resistance to Lestaurtinib (CEP-701) in culture (PMID: 21926964). | 21926964 |
JAK2 V617F JAK2 Y931C | hematologic cancer | resistant | Fedratinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing the JAK2 V617F and JAK2 Y931C double mutation demonstrated resistance to Inrebic (fedratinib) in culture (PMID: 21926964). | 21926964 |